Junhao Liu
No.139 Middle Renmin Road, 4100011
Changsha, 410001, China
Changsha, 410001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.
Journal: Breast cancer research and treatment
Published: February 22, 2023
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Journal: Cancer research
Published: February 28, 2022
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Journal: Breast cancer research : BCR
Published: November 07, 2021
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Journal: Cancer letters
Published: July 01, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Journal: Communications biology
Published: February 19, 2021
Identification of a Novel Transcription Factor Prognostic Index for Breast Cancer.
Journal: Frontiers in oncology
Published: February 10, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Journal: Cell death discovery
Published: January 07, 2021
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Journal: Breast cancer research and treatment
Published: July 13, 2020
PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.
Journal: Molecular carcinogenesis
Published: August 21, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026